The Asia Pacific Emphysema Treatment Market would witness market growth of 7.1% CAGR during the forecast period (2022-2028).
The alleviation of symptoms, the prevention of consequences, and the slowing down of the evolution of the illness are the objectives of treatment for emphysema. Patients diagnosed with emphysema should also make every effort to kick the habit of smoking as soon as possible since continuing to do so will only exacerbate the condition of their lungs.
Pulmonary rehabilitation is an essential component of the therapy for emphysema. This component involves education, dietary counseling, the learning of unique breathing methods, assistance with stopping smoking, and the beginning of an exercise routine. Emphysema patients often have physical limitations, so they may avoid any activity requiring them to move about. However, regular physical exercise is one of the best ways for a patient to enhance their health and well-being.
India is one of the nations with the highest population density, and it has a significant proportion of its population at least 60 years old. And it is anticipated that the percentage of elderly people living in India will continue to climb. According to the projections made by the country's government, the percentage will climb from 7.5% in 2010 to 11.1% in 2025.
China has one of the populations that is becoming older at one of the quickest rates in the world. It is anticipated that by the year 2040, the proportion of China's population that is over 60 years old will reach 28 percent, thanks to rising life expectancy and falling birth rates. As individuals live longer, their risk of developing chronic diseases like emphysema increases. This is especially true for older people. Because of this, it is anticipated that the market for emphysema treatments will grow in the area as the elderly population continues to grow.
The China market dominated the Asia Pacific Emphysema Treatment Market by Country in 2021, and would continue to be a dominant market till 2028; thereby, achieving a market value of $394.2 million by 2028. The Japan market is estimated to grow at a CAGR of 6.4% during (2022 - 2028). Additionally, The India market would exhibit a CAGR of 8% during (2022 - 2028).
Based on Medication Type, the market is segmented into Bronchodilators, Steroids, and Others. Based on Distribution Channel, the market is segmented into Drug Stores & Retail Pharmacies, Hospital Pharmacies, and Online Providers. Based on countries, the market is segmented into China, Japan, India, South Korea, Singapore, Malaysia, and Rest of Asia Pacific.
The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include AstraZeneca PLC, Teva Pharmaceuticals Industries Ltd., Novartis AG, Viatris, Inc., Orion Corporation, GlaxoSmithKline PLC, Pfizer, Inc., Hikma Pharmaceuticals PLC, Boehringer Ingelheim International GmbH and Verona Pharma Plc.
The alleviation of symptoms, the prevention of consequences, and the slowing down of the evolution of the illness are the objectives of treatment for emphysema. Patients diagnosed with emphysema should also make every effort to kick the habit of smoking as soon as possible since continuing to do so will only exacerbate the condition of their lungs.
Pulmonary rehabilitation is an essential component of the therapy for emphysema. This component involves education, dietary counseling, the learning of unique breathing methods, assistance with stopping smoking, and the beginning of an exercise routine. Emphysema patients often have physical limitations, so they may avoid any activity requiring them to move about. However, regular physical exercise is one of the best ways for a patient to enhance their health and well-being.
India is one of the nations with the highest population density, and it has a significant proportion of its population at least 60 years old. And it is anticipated that the percentage of elderly people living in India will continue to climb. According to the projections made by the country's government, the percentage will climb from 7.5% in 2010 to 11.1% in 2025.
China has one of the populations that is becoming older at one of the quickest rates in the world. It is anticipated that by the year 2040, the proportion of China's population that is over 60 years old will reach 28 percent, thanks to rising life expectancy and falling birth rates. As individuals live longer, their risk of developing chronic diseases like emphysema increases. This is especially true for older people. Because of this, it is anticipated that the market for emphysema treatments will grow in the area as the elderly population continues to grow.
The China market dominated the Asia Pacific Emphysema Treatment Market by Country in 2021, and would continue to be a dominant market till 2028; thereby, achieving a market value of $394.2 million by 2028. The Japan market is estimated to grow at a CAGR of 6.4% during (2022 - 2028). Additionally, The India market would exhibit a CAGR of 8% during (2022 - 2028).
Based on Medication Type, the market is segmented into Bronchodilators, Steroids, and Others. Based on Distribution Channel, the market is segmented into Drug Stores & Retail Pharmacies, Hospital Pharmacies, and Online Providers. Based on countries, the market is segmented into China, Japan, India, South Korea, Singapore, Malaysia, and Rest of Asia Pacific.
The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include AstraZeneca PLC, Teva Pharmaceuticals Industries Ltd., Novartis AG, Viatris, Inc., Orion Corporation, GlaxoSmithKline PLC, Pfizer, Inc., Hikma Pharmaceuticals PLC, Boehringer Ingelheim International GmbH and Verona Pharma Plc.
Scope of the Study
Market Segments Covered in the Report:
By Medication Type
- Bronchodilators
- Steroids
- Others
By Distribution Channel
- Drug Stores & Retail Pharmacies
- Hospital Pharmacies
- Online Providers
By Country
- China
- Japan
- India
- South Korea
- Singapore
- Malaysia
- Rest of Asia Pacific
Key Market Players
List of Companies Profiled in the Report:
- AstraZeneca PLC
- Teva Pharmaceuticals Industries Ltd
- Novartis AG
- Viatris, Inc
- Orion Corporation
- GlaxoSmithKline PLC
- Pfizer, Inc
- Hikma Pharmaceuticals PLC
- Boehringer Ingelheim International GmbH
- Verona Pharma Plc
Unique Offerings
- Exhaustive coverage
- The highest number of market tables and figures
- Subscription-based model available
- Guaranteed best price
- Assured post sales research support with 10% customization free
Table of Contents
Chapter 1. Market Scope & Methodology1.1 Market Definition
1.2 Objectives
1.3 Market Scope
1.4 Segmentation
1.4.1 Asia Pacific Emphysema Treatment Market, by Medication Type
1.4.2 Asia Pacific Emphysema Treatment Market, by Distribution Channel
1.4.3 Asia Pacific Emphysema Treatment Market, by Country
1.5 Methodology for the research
Chapter 2. Market Overview
2.1 Introduction
2.1.1 Overview
2.1.1.1 Market Composition & Scenario
2.2 Key Factors Impacting the Market
2.2.1 Market Drivers
2.2.2 Market Restraints
Chapter 3. Strategies Deployed in Emphysema Treatment Market
Chapter 4. Asia Pacific Emphysema Treatment Market by Medication Type
4.1 Asia Pacific Bronchodilators Market by Country
4.2 Asia Pacific Steroids Market by Country
4.3 Asia Pacific Others Market by Country
Chapter 5. Asia Pacific Emphysema Treatment Market by Distribution Channel
5.1 Asia Pacific Drug Stores & Retail Pharmacies Market by Country
5.2 Asia Pacific Hospital Pharmacies Market by Country
5.3 Asia Pacific Online Providers Market by Country
Chapter 6. Asia Pacific Emphysema Treatment Market by Country
6.1 China Emphysema Treatment Market
6.1.1 China Emphysema Treatment Market by Medication Type
6.1.2 China Emphysema Treatment Market by Distribution Channel
6.2 Japan Emphysema Treatment Market
6.2.1 Japan Emphysema Treatment Market by Medication Type
6.2.2 Japan Emphysema Treatment Market by Distribution Channel
6.3 India Emphysema Treatment Market
6.3.1 India Emphysema Treatment Market by Medication Type
6.3.2 India Emphysema Treatment Market by Distribution Channel
6.4 South Korea Emphysema Treatment Market
6.4.1 South Korea Emphysema Treatment Market by Medication Type
6.4.2 South Korea Emphysema Treatment Market by Distribution Channel
6.5 Singapore Emphysema Treatment Market
6.5.1 Singapore Emphysema Treatment Market by Medication Type
6.5.2 Singapore Emphysema Treatment Market by Distribution Channel
6.6 Malaysia Emphysema Treatment Market
6.6.1 Malaysia Emphysema Treatment Market by Medication Type
6.6.2 Malaysia Emphysema Treatment Market by Distribution Channel
6.7 Rest of Asia Pacific Emphysema Treatment Market
6.7.1 Rest of Asia Pacific Emphysema Treatment Market by Medication Type
6.7.2 Rest of Asia Pacific Emphysema Treatment Market by Distribution Channel
Chapter 7. Company Profiles
7.1 AstraZeneca PLC
7.1.1 Company Overview
7.1.2 Financial Analysis
7.1.3 Regional Analysis
7.1.4 Research & Development Expenses
7.1.5 Recent strategies and developments:
7.1.5.1 Partnerships, Collaborations, and Agreements:
7.1.5.2 Approvals and Trials:
7.2 Teva Pharmaceutical Industries Ltd.
7.2.1 Company Overview
7.2.2 Financial Analysis
7.2.3 Regional Analysis
7.2.4 Research & Development Expenses
7.2.5 Recent strategies and developments:
7.2.5.1 Product Launches and Product Expansions:
7.3 Novartis AG
7.3.1 Company Overview
7.3.2 Financial Analysis
7.3.3 Segmental and Regional Analysis
7.3.4 Research & Development Expense
7.3.5 Recent strategies and developments:
7.3.5.1 Approvals and Trials:
7.4 Viatris, Inc.
7.4.1 Company Overview
7.4.2 Financial Analysis
7.4.3 Segmental and Regional Analysis
7.4.4 Research & Development Expense
7.4.5 Recent strategies and developments:
7.4.5.1 Approvals and Trials:
7.5 Orion Corporation
7.5.1 Company Overview
7.5.2 Financial Analysis
7.5.3 Regional Analysis
7.5.4 Research & Development Expenses
7.5.5 Recent strategies and developments:
7.5.5.1 Partnerships, Collaborations, and Agreements:
7.6 GlaxoSmithKline PLC
7.6.1 Company Overview
7.6.2 Financial Analysis
7.6.3 Segmental and Regional Analysis
7.6.4 Research & Development Expense
7.6.5 Recent strategies and developments:
7.6.5.1 Product Launches and Product Expansions:
7.6.5.2 Approvals and Trials:
7.7 Pfizer, Inc.
7.7.1 Company Overview
7.7.2 Financial Analysis
7.7.3 Regional & Segmental Analysis
7.7.4 Research & Development Expense
7.8 Hikma Pharmaceuticals PLC
7.8.1 Company Overview
7.8.2 Financial Analysis
7.8.3 Segmental and Regional Analysis
7.8.4 Research & Development Expenses
7.9 Boehringer Ingelheim International Gmbh
7.9.1 Company Overview
7.9.2 Financial Analysis
7.9.3 Regional & Segmental Analysis
7.9.4 Research & Development Expenses
7.10. Verona Pharma Plc
7.10.1 Company Overview
7.10.2 Financial Analysis
7.10.3 Research & Development Expenses
Companies Mentioned
- AstraZeneca PLC
- Teva Pharmaceuticals Industries Ltd.
- Novartis AG
- Viatris, Inc.
- Orion Corporation
- GlaxoSmithKline PLC
- Pfizer, Inc.
- Hikma Pharmaceuticals PLC
- Boehringer Ingelheim International GmbH
- Verona Pharma Plc
Methodology
LOADING...
